Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
← catalyst calendarNCT06431776 · readout ≤ 314 d
Sponsored by Savara Inc. (industry) · SVRA — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
5estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-22 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Autoimmune Pulmonary Alveolar Proteinosis
Intervention
- Drug: Molgramostim — also filed as Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF).
Primary outcome
what the primary-completion date above is the date OFDLCO
measured 24 weeks
Permalink · SVRA's whole pipeline · Catalyst calendar · Every registered study · What changed